Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

Table 3 Multivariate Cox proportional hazard analysis for DFS and OS of patients with non-metastatic invasive breast cancer

	DFS			OS
	Hazard Ratio	P	95.0% CI for HR (range)	Hazard Ratio	P	95.0% CI for HR (range)
TNM stage^b	2.180	0.009	1.219–3.898	3.937	0.006	1.494–10.371
Signatures^b	1.560	0.138	0.866–2.810	2.085	0.091	0.889–4.890
Model before stepwise selection
Age^a	1.031	0.948	0.411–2.589	4.391	0.188	0.486–39.703
T status^b	2.613	0.010	1.255–5.439	3.679	0.028	1.148–11.793
N stage^b	1.222	0.512	0.671–2.225	1.125	0.815	0.420–3.010
Grade^b	1.142	0.750	0.504–2.585	4.189	0.027	1.180–14.867
HER-2/neu	0.928	0.884	0.342–2.520	0.066	0.016	0.007–0.606
Hormone Receptors	0.277	0.004	0.277–0.669	0.168	0.007	0.046–0.621
Signatures^b	2.063	0.041	1.031–4.126	4.850	0.014	1.374–17.122
Model after stepwise selection
T status^b	2.999	0.001	1.602–5.615	3.522	0.005	1.477–8.398
Hormone Receptors	0.269	0.002	0.116–0.621	0.231	0.014	0.072–0.742
Signatures^b	2.146	0.027	1.091–4.219	4.273	0.006	1.521–11.999

^aAge under 50 and over 50 years old
^bAll categorical covariates were transformed into numeric codes as follows : T status (T1; 1, T2; 2, T3; 3), N stage (N0; 0, N1; 1, N2; 2, N3; 3), Grade (G1; 1, G2; 2, G3; 3), Signatures (FCIS; 1, Rest; 2, UCIS; 3) TNM stage (I; 1, II; 2, III; 3)